January Commentary: Lowland



January was a mixed month for the Trust as some holdings came back in share price terms. The largest individual detractor was Carclo, following news that its touch-screen technology will grow slower than initially expected. Over the medium term we continue to believe that the company can grow substantially.

Despite strong domestic economic data, UK equity markets fell during January as a result of worries surrounding emerging markets. For companies held within the Trust, strong fourth quarter UK GDP data and a reduction in the unemployment rate will ultimately prove more important for sales and earnings growth than emerging market fluctuations, and therefore we remain comfortable with the Trust’s positioning in high quality manufacturing companies.

Buying and selling activity remained low this month as we continue to run with our winners. We added to the position in pharmaceutical firm AstraZeneca, as it is taking active steps to improve its research and development pipeline, which over the long term should result in earnings and dividend growth. The positions in Irish insurer FBD Holdings and Interserve were trimmed; we continue to see value in these names but feel it is prudent to take profits following large price moves.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.




Important message

Fund name changes

Please note that from the 15 December 2017 funds previously named Janus or Henderson have been renamed Janus Henderson. This change aligns our product names with our name, Janus Henderson Investors, following the merger of Janus Capital and Henderson Global Investors in May 2017.

This name change does not impact on the management of the underlying funds and investors and advisers are not required to take any action.